Proparacaine HCl Ophthalmic Solution Rx
Generic Name and Formulations:
Proparacaine HCl 0.5%; contains benzalkonium chloride.
Various generic manufacturers
Indications for Proparacaine HCl Ophthalmic Solution:
For procedures in which a topical ophthalmic anesthetic is indicated: corneal anesthesia of short duration (eg, tonometry, gonioscopy, removal of corneal foreign bodies), and for short corneal and conjunctival procedures.
Adults and Children:
Removal of foreign bodies and sutures, and for tonometry: 1–2 drops in each eye before operating. Short corneal and conjunctival procedures: 1 drop in each eye every 5–10 minutes for 5–7 doses.
Not for injection into eye. Permanent corneal opacification with accompanying visual loss with prolonged use. Pregnancy (Cat.C). Nursing mothers.
Rapidly-acting topical anesthetic.
Local effects (eg, stinging, burning, conjunctival redness); rare: severe, immediate-type hyperallergic corneal reaction.
Formerly known under the brand name Ophthetic.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML
- Nicotinamide and Cancer
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma